Biomarkers

A gut microbiome-based model could help predict responses to Entyvio vedolizumab in Crohn's disease and UC patients. Metagenomic analysis of fecal samples from 42 Crohn's disease patients receiving Entyvio identified associations between post-treatment disease remission and high pretreatment levels of Roseburia inulinivorans, Burkholderiales sp., and microbial genes encoding 13 metabolic pathways in the gut microbiome. Metagenomic analysis of fecal samples from 43 UC patients receiving Entyvio identified associations between post-treatment disease remission and high pretreatment levels of microbial genes encoding two metabolic pathways, and low pretreatment levels of genes encoding three metabolic pathways in the gut microbiome. Also in fecal samples from the two patient groups, a neural network model trained on 40 variables, including levels of microbes and microbial genes encoding metabolic pathways in fecal samples, correctly identified patients who did and did not respond to Entyvio with an area under the curve (AUC) of 0.872. Next steps could include validating the model in a larger cohort of Crohn's disease and UC patients...